Yes, ONPATTRO Is a Silencer: A Deep Dive into its Innovative Pharmacology
•
4 min read
In 2018, ONPATTRO became the first FDA-approved medication using RNA interference technology, ushering in a new era of gene-based medicines. The groundbreaking therapy acts as a gene silencer, specifically targeting and reducing the production of a protein responsible for a rare, debilitating genetic disease known as hATTR amyloidosis.
